BridgeBio Pharma, Inc. — Director's Dealing 2024

Dec 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-12-10

Reporting Person: Kumar Neil (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-10	Restricted Stock Units	$	A	121951	Acquired		Common Stock (121951)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.